

# The Utilization of Bariatric Surgery in Patients with and without Diabetes: Results from the Second Kuwait National Bariatric Surgery Database Report

Salman Al Sabah (✉ [salman.k.alsabah@gmail.com](mailto:salman.k.alsabah@gmail.com))

Kuwait University

Eliana Al Haddad

Al Amiri Hospital

---

## Research Article

**Keywords:** National Registry, Metabolic Surgery, Bariatric Surgery, Diabetes, Gulf.

**Posted Date:** June 1st, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1606008/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

During the year 2021, we were able to create the second Kuwait National Bariatric Surgery Database Report, which we used to extract data on the status and outcomes of patients presenting with type 2 diabetes mellitus (T2DM) undergoing bariatric-metabolic surgery in Kuwait.

## Methods

Data was collected from seven public hospitals in Kuwait, and submitted to be merged in the National Registry. Cross-sectional analysis was then conducted.

## Results

All seven hospitals contributed to the submission of data. The rate of T2DM was 12.5% (607 patients), of which 69% were female. The mean age of patients with T2DM was higher than that of patients without (42 years vs 31.9 years). The overall BMI was slightly higher for patients with T2DM (mean 43.4kg/m<sup>2</sup> vs 43.1kg/m<sup>2</sup>). The majority of patients with T2DM were in the BMI range 40.0-49.9kg/m<sup>2</sup>. Laparoscopic sleeve gastrectomy accounted for 79.0% of all procedures performed in non-diabetic patients and 79.7% of those performed in diabetic patients. When looking at surgical procedure distribution when classified according to starting BMI group in diabetic patients, it was interesting to see that, in Group 1 (BMI <35), sleeve gastrectomy only accounted for 47.2%, while in the larger BMI groups (>35), sleeve gastrectomy accounted for 82.6-83.2% of all procedures performed. When comparing post-op complications between diabetic vs non-diabetic patients, the percentage of overall complications encountered did not show a significant difference (1.81% vs 2.10% ; p=0.602). When looking at cardiovascular complications, patients with diabetes tended to present with higher post-op cardiac complications compared to non-diabetics (p=0.000).

## Conclusion

Laparoscopic sleeve gastrectomy was the most performed procedure in both diabetics and non diabetics alike. Patients with diabetes tended to present for surgery at an older age than those without. It was interesting, albeit possibly expected, to note that patients with diabetes presented with a higher percentage of a multitude of complications post-operatively, pointing towards the importance of post-operative care in diabetic patients that present for bariatric surgery.

## Background

The twin epidemic of obesity and diabetes has become a major global crisis (1). With cardiovascular disease still remaining the leading cause of death around the world (2), and diabetes being a major contributor to cardiovascular disease, the influence of obesity to diabetes has gained significant weight. Diabetes mellitus (DM) is a chronic condition caused by the absence of insulin secretion, either due to the

inability of the pancreas cells to produce insulin, or due to defects in insulin uptake in peripheral tissue. The disease consequently has the ability to alter carbohydrate, protein and fat metabolism (3), contributing to the vicious cycle that links diabetes to obesity.

It has been proven that women with a body mass index (BMI) exceeding 30 kg/m<sup>2</sup> have a 28x greater risk of developing diabetes, with the risk reaching 93 times greater in those with a BMI of 35 kg/m<sup>2</sup>, compared to those with a normal weight (4). Bariatric and metabolic surgery has consistently proven its benefits for patients presenting with type 2 diabetes mellitus (T2DM) and severe obesity, compared to medical therapy alone, via randomized controlled trials (5–8), international guidelines (9–11), as well as systemic reviews and meta-analysis (12, 13). Metabolic surgery is defined as ‘the operative manipulation of a normal organ or organ system to achieve a biological result for a potential health gain’, and therefore encompasses interventions that cause a positive impact on the management of T2DM (14).

Currently, few comparative data exist that exhibit worldwide patient results that are receiving bariatric-metabolic surgery (15, 16). Therefore, the ability to map these current international practices could provide a baseline for the development of strategies to increase the availability and uptake of bariatric surgery. The International Federation of Surgery for Obesity (IFSO) has embarked on undertaking several surveys and reports, mostly relying on estimates, over the last 20 years (17–21). These reports were able to describe only operation type and procedure numbers, without detailed correlation on demography or obesity-related disease. A description of which patients with T2DM are receiving bariatric-metabolic surgery and whether having T2DM influences the procedure undertaken is currently lacking, especially in the Arab world.

During the year 2021, we were able to create the second Kuwait National Bariatric Surgery Database Report to report on bariatric surgeries performed in Government hospitals in Kuwait, baseline obesity-related diseases, operation types, operative outcomes and status after bariatric surgery. From this report, we aim to describe the differences in demographic data and type of bariatric and metabolic surgery performed in patients with and without T2DM.

## Methods

### National database data collection

A cross-sectional study was performed of the baseline data for patients with or without T2DM having primary bariatric surgery from the Kuwait National Registry 2021 data cut. For the report, permission was obtained from the ministry of health to collect data from the seven public hospitals in Kuwait on bariatric results and outcomes. Invitations were sent to bariatric surgeons working in these hospitals, of which 66 contributed to the data collection. This data was then submitted to a merged National Registry. A Direct Data Entry system, and an Upload-My-Data web portal were used to upload, merge, and analyze the data. Data was collected on 4,862 cases, of which 3,963 were primary procedures (**Table 1**). Data collection was demonstrably of a very high quality; over 87% of entries for patients having their primary operation

had either no missing data or one missing data-item amongst a list of 10 obesity-related diseases assessed pre-operatively. All patients provided written consent prior to undergoing their procedure.

## Definition of Diabetes

We aimed to set a standard baseline for defining obesity related diseases as to be able to compare between individual patients. Positive responses (data denoting patients who have the condition) for Type 2 diabetes were:

1. Impaired glycaemia or impaired glucose tolerance.
2. Insulin treatment.
3. OAD & insulin treatment.
4. Oral hypoglycaemics.

## Procedures

The procedures in the data set were as described previously and comprised gastric balloon/gastric band/gastric bypass/sleeve gastrectomy/duodenal switch/biliopancreatic diversion/other, and type of gastric bypass: Roux-en-Y (RYGB) or one anastomosis gastric bypass (OAGB).

## Outcomes

Other variables collected were age or date of birth, sex, height, weight, T2DM defined as mentioned earlier. Only valid records, defined as those including height, weight and calculated BMI, were included for analysis. Data were grouped according to T2DM on medication, age, sex and BMI. The BMI groups were stratified according to obesity severity < 35.0 (class I), 35.0–39.9 (class II), 40.0–49.9 (class III), and > 49.9 kg/m<sup>2</sup>. Types of operation were assessed to investigate practice undertaken for T2DM according to BMI groupings.

## Data analysis

Descriptive statistics were used for the analysis of the data. Furthermore, as data from different hospitals may only provide variable representation of the population, no comparative analysis was performed between hospitals.

On the whole, unless otherwise stated, the tables and charts in this report record the number of procedures. The numbers in each table are bolded so that entries with complete data for all of the components under consideration are shown in regular black text. If one or more of the database questions under analysis is blank, the data are reported as unspecified in bold text. The totals for both rows and columns are highlighted as italic text. Some tables record percentage values; in such cases this is made clear by the use of an appropriate title within the table and a % symbol after the numeric value.

Rows and columns within tables have been ordered so that they are either in ascending order or with negative response options first (No; None) followed by positive response options (Yes; One, Two, etc.).

# Graphs

All entries with missing data are excluded from the analysis used to generate the graph. In the charts prepared for this report, most of the bars plotted around rates (percentage values) represent 95% confidence intervals. The width of the confidence interval provides some idea of how certain we can be about the calculated rate of an event or occurrence. If the intervals around two rates do not overlap, then we can say, with the specified level of confidence, that these rates are different; however, if the bars do overlap, we cannot make such an assertion.

Bars around averaged values (such as patients' age, post-operative length-of-stay, etc.) are classical standard error bars or 95% confidence intervals; they give some idea of the spread of the data around the calculated average. In some analyses that employ these error bars there may be insufficient data to legitimately calculate the standard error around the average for each sub-group under analysis; rather than entirely exclude these low-volume sub-groups from the chart their arithmetic average would be plotted without error bars. Such averages without error bars are valid in the sense that they truly represent the data submitted; however, they should not to be taken as definitive and therefore it is recommended that such values are viewed with extra caution.

## Results

Figure 1 demonstrates the completeness of the obesity-related disease data for entries where only one data-item is missing, and for all entries in the central Kuwait National Bariatric Surgery Registry. Where a single data-item is missing, it was largely liver disease, sleep apnea, dyslipidemia and back / leg pain questions that have not been completed. Across the board, the biggest issues seem to be with the same four questions in the database.

## Demographic Characteristics of Those with and without T2DM

The number on medication for T2DM was 607, with females accounting for 69.1% of the population of patients defined as having type 2 diabetes mellitus. Males with diabetes accounted for 4% of the overall population, while females accounted for 8.9% ( $p = 0.000$ ) (Table 2). The mean age of patients with T2DM was higher than that of patients without (overall mean age 42 (11.2) years vs 31.9 (10.5) years). The mean ages of men and women with T2DM were 41.8 (10.8) years and 42.1 (11.4) years.

The overall BMI was slightly higher for patients with T2DM (mean 43.4 (8.3)  $\text{kg}/\text{m}^2$  vs 43.1 (8.3)  $\text{kg}/\text{m}^2$ ). The majority of patients with T2DM were in the BMI range 40.0-49.9  $\text{kg}/\text{m}^2$  (Table 3). The proportion of patients with T2DM in each obesity class can be seen in Fig. 2. The proportion of female patients with diabetes exceeded that of males in every BMI group.

## Procedure Performed Based on T2DM Status

Alone, laparoscopic sleeve gastrectomy (SG) accounted for 79.0% of all procedures performed in non-diabetic patients and 79.7% of those performed in diabetic patients. Mini-gastric bypass (OAGB) accounted for 10.4% of procedures performed in diabetics, followed by Roux-en-Y Gastric Bypass (RYGB), which accounted for 6.4% (**Table 4**, Fig. 3). When looking at surgical procedure distribution when classified according to starting BMI group in diabetic patients, it was interesting to see that, in Group 1 (BMI < 35), sleeve gastrectomy only accounted for 47.2%, while in the larger BMI groups (> 35), sleeve gastrectomy accounted for 82.6–83.2% of all procedures performed, pointing to a favor for SG's in the larger BMI population of diabetics (**Table 5**).

## Post-Op Complications

When comparing post-op complications between diabetic vs non-diabetic patients, the percentage of overall complications encountered in patients with T2DM vs non-diabetic did not show a significant difference (1.81% vs 2.10% ;  $p = 0.602$ ), while the percentage of other complications can be seen presented in **Table 6**. It is interesting to note that bleeding (0.49 vs 0.46%), port site infection (0.33 vs 0.29%), pneumonia/atelectasis/RTI (0.82 vs 0.24%), and unanticipated transfer to the ICU (1.81 vs 0.41%) were the only complications that were shown to be higher in patients with T2DM as compared to non-diabetics. When looking at cardiovascular complications, patients with diabetes tended to present with higher post-op cardiac complications (dysrhythmia, pulmonary embolism, and other) compared to non-diabetics ( $p = 0.000$ ) (**Table 7**).

## Discussion

In the face of this accelerated standard of living and modernization through communication, an emergent market may directly even further impact these present dire conditions (22). In the last decade, home delivery of foods has been revolutionized in Kuwait 8. Through the development of smartphone applications, ordering a high caloric meal with none to minimal movement has become possible through the click of a button (23). This, in turn, is a recipe for disaster in terms of the growing rates of obesity, and subsequently, diabetes. In terms of the increasing population amongst the youth and adolescents that presently constitute 80% of the non-diabetic obese population, the risk factors based on genetics put these demographics at risk for developing diabetes (24). While obesity itself is considered a debilitating condition, major studies have clearly correlated obesity with the development of chronic metabolic disorders such as diabetes, hypertension, and hyperlipidemia and reduced quality of life, shorter life expectancy, and an overall increase in the cost of care (22).

Chronic metabolic disorders are complex diseases that need ongoing care and management (25). Of the many lifestyle factors such as lack of exercise, a poor diet, and smoking, being overweight has been identified as the most critical predictor of obesity-related diseases (1).

In the Arabian Gulf region, due to the high prevalence of obesity and the lack of national screening programs and routine medical checkups, there is a higher potential for the delay in diagnosis and commencement of treatment that increases the risks of complications, metabolic comorbidities, and

mortalities (26). Some of the complications of uncontrolled diabetes include diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, macrovascular events like cardiovascular diseases and diabetic foot ulcers, and amputations (27). According to the International Diabetes Federation's publication titled Diabetes Atlas, Kuwait is ranked amongst the top 10 countries with a national prevalence of 22% in adults aged 20–79 years (28). While diabetes can be controlled and managed with oral hypoglycemic agents, insulin, and lifestyle modification such as diet and exercise, recent updates from the Standards of Medical Care published by the American Diabetes Association also recommend metabolic surgery to manage diabetes in appropriate obese patients (27, 29).

Metabolic surgeries have opened a new door for the management of obese patients with diabetes and became accepted as a safe and effective method for treating and controlling diabetes in the obese population (30–34). The American Diabetes Association, 2018 Standards of Care for the Management of Obesity and diabetes indicates that metabolic surgery is an effective treatment to improve weight loss measures and is beneficial in treating diabetes (27, 29). In fact, no other treatment has produced such durable and ample control of diabetes (9, 31, 32). Accordingly, in a study conducted by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) of 42 countries that indicated metabolic trends worldwide, Kuwait ranks number one for the frequency of metabolic procedures performed as a percentage of the national population (20, 33).

In terms of surgery, there are many types of metabolic surgeries performed to manage obesity, e.g., Roux-en-Y Gastric Bypass, Adjustable Gastric Band, and Laparoscopic Sleeve Gastrectomy (35). Bariatric surgery is instrumental in treating metabolic syndrome with significant remission or improvement in most cases (31, 32, 34, 35). Metabolic outcomes have improved over time with these surgical procedures. While all these procedures have been studied in relation to metabolic syndrome and obesity, LSG has been gaining popularity and is the highest performed surgery in the Arabian Gulf region and especially Kuwait for the management of obesity (32, 34, 36–40).

In terms of funding in Kuwait, bariatric / metabolic surgery is covered by the government sector (Ministry of Health) with the exception of medical equipment specific to the procedure like ports, stapler, energy device etc. Ministry of Health covers pre-operative, intra-operative, and post-operative care, including clinical investigations, doctor visits, operating room fees, multidisciplinary bariatric team professional visits, and hospital stays. Additionally, the Ministry of Health covers the management of complications, revisional procedures, and international visitors workshops for challenging cases. Ministry of Health also covers international care for eligible patients abroad. Bariatric procedures performed in private-sector hospitals are not covered by insurance. However, the government covers complications that originate from private sector bariatric procedures.

With the increasing frequency of bariatric procedures performed in Kuwait and Kuwait ranked as one of the highest countries for the frequency of bariatric surgeries performed, collecting this growing body of data into national registries is crucial. One of the most essential facets of collecting this data is the need

for standardization in reporting the different comorbidities. In this report, there is a need to include more complete details on patients consistently and accurately (41).

It remains a goal for the future to incorporate data from all key stakeholders in bariatric surgery, especially surgeons, and physicians to embrace this data collection and reporting process at individual clinics and hospitals. It will require widespread involvement and ongoing commitment from all those involved in the care of the bariatric patient to ensure high-quality data can be collected, properly analyzed and shared, so that we will be better able to understand shifts in disease patterns, practice, and outcomes on a national scale. Therefore, the data is presented using a small and far from comprehensive dataset, as simple tables and graphs usually 2 variables, one for each axis, plus a dedicated commentary for each.

## Conclusion

Laparoscopic sleeve gastrectomy was shown to be the most performed procedure in both diabetics and non diabetics alike, having similar numbers in the 2 populations. Patients with diabetes tended to present for surgery at an older age, with higher BMI's than those without. The number of female patients exceeded male patients for all BMI groups. It was interesting, albeit possibly expected, to note that patients with diabetes presented with a higher percentage of a multitude of complications post-operatively, included cardiac, pointing towards the importance of post-operative care in diabetic patients that present for bariatric surgery.

## Abbreviations

BMI

Body mass index

BPD/DS

biliopancreatic bypass +/- duodenal switch

EWL

percent Excess Weight Loss

LAGB

laparoscopic adjustable gastric banding

RYGB

Roux-en-Y gastric bypass

IFSO

International Federation for the Surgery of Obesity and Metabolic Surgery of Obesity and Metabolic Disorders

H2RA

H2 receptor antagonists

PPI

Proton pump inhibitors



DVT  
Deep vein thrombosis  
PE  
Pulmonary embolus  
OAGB  
one anastomosis gastric bypass  
OSMRS  
Obesity Surgery Mortality Risk Score  
GERD  
Gastro-esophageal reflux disorder  
OAGB/MGB  
Single anastomosis gastric bypass

## **Declarations**

### **Ethics approval and consent to participate**

All patients provided written consent prior to undergoing the procedures. Informed consent was obtained from parents of patients aged 16 years or younger. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics Committee approval was obtained from the Kuwait Ministry of Health prior to commencement of the study.

### **Consent to publish**

Not Applicable.

### **Competing interests**

The authors declare that they have no conflict of interest.

### **Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### **Funding**

The authors declare no source of funding for the completion of this study.

### **Authors Contributions**

SA conceptualized the idea and brought together all the authors, as well as collected the data from the hospitals; EA analyzed the data and wrote the manuscript. All authors have read and approved the manuscript.

## Acknowledgments

We would like to thank Kuwait University Research Sector for their support in producing this data.

## References

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001. *JAMA*. 2003;289(1):76–9.
2. About Underlying Cause of Death, 1999–2020 Center for Disease Control 2021 [Available from: <https://wonder.cdc.gov/ucd-icd10.html>].
3. Scheen AJ. Pathophysiology of type 2 diabetes. *Acta Clin Belg*. 2003;58(6):335–41.
4. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Intern Med*. 1995;122(7):481–6.
5. Cheng J, Gao J, Shuai X, Wang G, Tao K. The comprehensive summary of surgical versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials. *Oncotarget*. 2016;7(26):39216–30.
6. Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. *Jama*. 2018;319(3):241–54.
7. Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. *Jama*. 2018;319(3):255–65.
8. Hofsø D, Fatima F, Borgeraas H, Birkeland KI, Gulseth HL, Hertel JK, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2019;7(12):912–24.
9. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. *Diabet Med*. 2011;28(6):628–42.
10. Stegenga H, Haines A, Jones K, Wilding J. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. *Bmj*. 2014;349:g6608.
11. Welbourn R, Hopkins J, Dixon JB, Finan N, Hughes C, Viner R, et al. Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. *Obes Rev*. 2018;19(1):14–27.
12. Avenell A, Robertson C, Skea Z, Jacobsen E, Boyers D, Cooper D, et al. Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and

- economic evaluation. *Health Technol Assess.* 2018;22(68):1–246.
13. Borgeraas H, Hofso D, Hertel JK, Hjelmessaeth J. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev.* 2020;21(6):e13011.
  14. Buchwald H VR. In: Varco HBRL, editor. *Metabolic surgery (modern surgical monographs)*: Grune & Stratton; 1978. p. 329.
  15. Welbourn R, Pournaras DJ, Dixon J, Higa K, Kinsman R, Ottosson J, et al. *Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Second IFSO Global Registry Report 2013–2015.* *Obes Surg.* 2018;28(2):313–22.
  16. Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, et al. *Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018.* *Obes Surg.* 2019;29(3):782–95.
  17. Buchwald H, Williams SE. *Bariatric surgery worldwide 2003.* *Obes Surg.* 2004;14(9):1157–64.
  18. Buchwald H, Oien DM. *Metabolic/bariatric surgery Worldwide 2008.* *Obes Surg.* 2009;19(12):1605–11.
  19. Buchwald H, Oien DM. *Metabolic/bariatric surgery worldwide 2011.* *Obes Surg.* 2013;23(4):427–36.
  20. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N. *Bariatric Surgery Worldwide 2013.* *Obes Surg.* 2015;25(10):1822–32.
  21. Angrisani L, Santonicola A, Iovino P, Vitiello A, Higa K, Himpens J, et al. *IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures.* *Obes Surg.* 2018;28(12):3783-94.
  22. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. *Obes Rev.* 2011;12(2):131–41.
  23. Musaiger AO. Consumption, health attitudes and perception toward fast food among Arab consumers in Kuwait: gender differences. *Glob J Health Sci.* 2014;6(6):136–43.
  24. Al-Kandari YY. Prevalence of obesity in Kuwait and its relation to sociocultural variables. *Obes Rev.* 2006;7(2):147–54.
  25. Welbourn R, Hollyman M, Kinsman R, Dixon J, Cohen R, Morton J, et al. *Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015–2018.* *Obes Surg.* 2021;31(6):2391–400.
  26. Ng SW, Zaghoul S, Ali HI, Harrison G, Popkin BM. The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States. *Obes Rev.* 2011;12(1):1–13.
  27. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med.* 1998;15(7):539–53.
  28. *Diabetes around the world in 2021: IDF Diabetes Atlas; 2022* [Available from: <https://diabetesatlas.org/>].

29. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S65-s72.
30. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. *Ann Surg*. 1995;222(3):339–50; discussion 50 – 2.
31. Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes. *Diabetes Care*. 2016;39(6):902–11.
32. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Diabetes Care*. 2016;39(6):861–77.
33. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ: British Medical Journal*. 2013;347:f5934.
34. Aminian A, Brethauer SA, Andalib A, Puchai S, Mackey J, Rodriguez J, et al. Can Sleeve Gastrectomy "Cure" Diabetes? Long-term Metabolic Effects of Sleeve Gastrectomy in Patients With Type 2 Diabetes. *Ann Surg*. 2016;264(4):674–81.
35. Demaria EJ, Winegar DA, Pate VW, Hutcher NE, Ponce J, Pories WJ. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. *Ann Surg*. 2010;252(3):559–66; discussion 66 – 7.
36. Murphy R, Evennett NJ, Clarke MG, Robinson SJ, Humphreys L, Jones B, et al. Sleeve gastrectomy versus Roux-en-Y gastric bypass for type 2 diabetes and morbid obesity: double-blind randomised clinical trial protocol. *BMJ Open*. 2016;6(7):e011416.
37. Musella M, Apers J, Rheinwalt K, Ribeiro R, Manno E, Greco F, et al. Efficacy of Bariatric Surgery in Type 2 Diabetes Mellitus Remission: the Role of Mini Gastric Bypass/One Anastomosis Gastric Bypass and Sleeve Gastrectomy at 1 Year of Follow-up. A European survey. *Obes Surg*. 2016;26(5):933–40.
38. Ugale SM, Celik A. Ileal Interposition with Sleeve Gastrectomy for Type 2 Diabetes Mellitus and Metabolic Syndrome. In: Agrawal S, editor. *Obesity, Bariatric and Metabolic Surgery: A Practical Guide*. Cham: Springer International Publishing; 2016. p. 547–54.
39. Vidal J, Ibarzabal A, Romero F, Delgado S, Momblán D, Flores L, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. *Obes Surg*. 2008;18(9):1077–82.
40. Nimeri A, Al Hadad M, Khoursheed M, Maasher A, Al Qahtani A, Al Shaban T, et al. The Peri-operative Bariatric Surgery Care in the Middle East Region. *Obes Surg*. 2017;27(6):1543–7.
41. AlMarri F, Al Sabah S, Al Haddad E, Vaz JD. A Call for More Research from the Arabian Gulf. *Obes Surg*. 2017;27(8):2034–43.

# Tables

Table 1

| Hospital                   | Count        |
|----------------------------|--------------|
| Al Adan Hospital           | 455          |
| Al Amiri Hospital          | 1,386        |
| Al Jahra Hospital          | 726          |
| Al Sabah Hospital          | 723          |
| Farwaniya Hospital         | 555          |
| Jaber Hospital             | 169          |
| Mubarak Al-Kabeer Hospital | 848          |
| <b>All</b>                 | <b>4,862</b> |

Table 2: Proportion of patients with DM according to Gender

|                |            | T2DM  |       | Total  |
|----------------|------------|-------|-------|--------|
|                |            | 0     | 1     |        |
| <b>Gender</b>  | Count      | 5     | 0     | 5      |
|                | % of Total | 0.1%  | 0.0%  | 0.1%   |
| <b>Female</b>  | Count      | 3095  | 419   | 3514   |
|                | % of Total | 65.7% | 8.9%  | 74.6%  |
| <b>Male</b>    | Count      | 1004  | 187   | 1191   |
|                | % of Total | 21.3% | 4.0%  | 25.3%  |
| <b>Unknown</b> | Count      | 0     | 1     | 1      |
|                | % of Total | 0.0%  | 0.0%  | 0.0%   |
| <b>Total</b>   | Count      | 4104  | 607   | 4711   |
|                | % of Total | 87.1% | 12.9% | 100.0% |

P=0.000

Table 3

|                                |            | DM         |       | Total  |       |
|--------------------------------|------------|------------|-------|--------|-------|
|                                |            | 0          | 1     |        |       |
| BMI group (Kg/m <sup>2</sup> ) | <35        | Count      | 349   | 53     | 402   |
|                                |            | % of Total | 7.7%  | 1.2%   | 8.8%  |
|                                | 35-39.9    | Count      | 1062  | 173    | 1235  |
|                                |            | % of Total | 23.3% | 3.8%   | 27.1% |
|                                | 40-49.9    | Count      | 2008  | 270    | 2278  |
|                                |            | % of Total | 44.0% | 5.9%   | 49.9% |
|                                | >49.9      | Count      | 541   | 105    | 646   |
|                                |            | % of Total | 11.9% | 2.3%   | 14.2% |
| Total                          | Count      | 3960       | 601   | 4561   |       |
|                                | % of Total | 86.8%      | 13.2% | 100.0% |       |

P=0.022

Table 4

|           |                            | DM         |       | Total |        |
|-----------|----------------------------|------------|-------|-------|--------|
|           |                            | 0          | 1     |       |        |
| Operation | Bilio-pancreatic diversion | Count      | 0     | 1     | 1      |
|           |                            | % of Total | 0.0%  | 0.0%  | 0.0%   |
|           | Duodenal switch            | Count      | 13    | 1     | 14     |
|           |                            | % of Total | 0.3%  | 0.0%  | 0.3%   |
|           | Gastric balloon            | Count      | 279   | 8     | 287    |
|           |                            | % of Total | 5.9%  | 0.2%  | 6.1%   |
|           | Gastric band               | Count      | 125   | 8     | 133    |
|           |                            | % of Total | 2.7%  | 0.2%  | 2.8%   |
|           | Mini-gastric bypass        | Count      | 245   | 63    | 308    |
|           |                            | % of Total | 5.2%  | 1.3%  | 6.5%   |
|           | Other                      | Count      | 18    | 3     | 21     |
|           |                            | % of Total | 0.4%  | 0.1%  | 0.4%   |
|           | Roux en Y gastric bypass   | Count      | 177   | 39    | 216    |
|           |                            | % of Total | 3.8%  | 0.8%  | 4.6%   |
|           | Sleeve gastrectomy         | Count      | 3247  | 484   | 3731   |
|           |                            | % of Total | 68.9% | 10.3% | 79.2%  |
| Total     |                            | Count      | 4104  | 607   | 4711   |
|           |                            | % of Total | 87.1% | 12.9% | 100.0% |

P=0.000

Table 5

|                            | <b>BMI Group 1 (&lt;35)</b> | <b>BMI Group 2 (35-39.9)</b> | <b>BMI Group 3 (40-49.9)</b> | <b>BMI Group 4 (&gt;50)</b> |
|----------------------------|-----------------------------|------------------------------|------------------------------|-----------------------------|
| <b>BPD</b>                 | 0.0%                        | 0.6%                         | 0.0%                         | 0.0%                        |
| <b>Duodenal Switch</b>     | 0.0%                        | 0.0%                         | 0.0%                         | 0.9%                        |
| <b>Gastric balloon</b>     | 3.8%                        | 1.2%                         | 0.4%                         | 2.7%                        |
| <b>Gastric band</b>        | 11.3%                       | 0.6%                         | 0.4%                         | 0.0%                        |
| <b>Mini-Gastric bypass</b> | 13.2%                       | 8.1%                         | 11.9%                        | 9.0%                        |
| <b>RYGB</b>                | 22.6%                       | 6.4%                         | 4.1%                         | 4.5%                        |
| <b>Sleeve Gastrectomy</b>  | 47.2%                       | 83.2%                        | 82.6%                        | 82.9%                       |
| <b>Other</b>               | 1.9%                        | 0.0%                         | 0.2%                         | 0.0%                        |

Table 6

| Complication                          | Number (n)          |             | Percentage (%)      |             |
|---------------------------------------|---------------------|-------------|---------------------|-------------|
|                                       | <b>Non-diabetic</b> | <b>T2DM</b> | <b>Non-diabetic</b> | <b>T2DM</b> |
| <b>Acute cholecystitis/CBD stones</b> | 3                   | 0           | 0.07%               | 0%          |
| <b>Bleeding</b>                       | 19                  | 3           | 0.46%               | 0.49%       |
| <b>Leak</b>                           | 7                   | 0           | 0.17%               | 0%          |
| <b>Port site infection</b>            | 12                  | 2           | 0.29%               | 0.33%       |
| <b>Pneumonia/atelectasis/RTI</b>      | 10                  | 5           | 0.24%               | 0.82%       |
| <b>Vomiting/poor intake</b>           | 108                 | 12          | 2.63%               | 1.98%       |
| <b>Wound Infection</b>                | 18                  | 0           | 0.44%               | 0%          |
| <b>Unanticipated transfer to ICU</b>  | 17                  | 11          | 0.41%               | 1.81%       |

Table 7



| Complication | Number (n)   |      | Percentage (%) |       |
|--------------|--------------|------|----------------|-------|
|              | Non-diabetic | T2DM | Non-diabetic   | T2DM  |
| DVT          | 1            | 0    | 0.02%          | 0%    |
| Dysrhythmia  | 44           | 18   | 1.07%          | 2.97% |
| PE           | 6            | 3    | 0.15%          | 0.49% |
| Other        | 68           | 17   | 1.66%          | 2.80% |

## Figures






Figure 1

Completeness of the obesity-related disease data for entries where only one data-item is missing, and for all entries in the central Kuwait National Bariatric Surgery Registry



**Figure 2**

Diabetes Rates for Males and Females in General Population



**Figure 3**

Procedures Performed Based on T2DM Status